Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S095033 and Paclitaxel in Advanced or Metastatic ESCC
NCT05312372Phase 2Withdrawn
- Sponsor
- Servier
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of S095033 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Servier. Primary endpoints: Dose-limiting toxicities at 28 days, Adverse events up to 4 years and 1 more. Planned start May 2025; status: withdrawn.
02
Drugs
S095033
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05312372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312372.